These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2421 related articles for article (PubMed ID: 32457745)

  • 1. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
    Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
    Front Immunol; 2020; 11():223. PubMed ID: 32133005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Therapy Opportunities in Ovarian Cancer.
    Kandalaft LE; Odunsi K; Coukos G
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
    Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
    Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Firing up "cold" tumors: Ferroptosis causes immune activation by improving T cell infiltration.
    Li X; Li Y; Tuerxun H; Zhao Y; Liu X; Zhao Y
    Biomed Pharmacother; 2024 Oct; 179():117298. PubMed ID: 39151313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
    Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
    Front Immunol; 2021; 12():754436. PubMed ID: 34733287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance.
    Bell HN; Zou W
    Annu Rev Immunol; 2024 Jun; 42(1):521-550. PubMed ID: 38382538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turning Cold into Hot: Firing up the Tumor Microenvironment.
    Duan Q; Zhang H; Zheng J; Zhang L
    Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
    Huang X; Zhang W
    Small Methods; 2024 Aug; 8(8):e2301326. PubMed ID: 38040834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 122.